LLY

1,078.02

+0.1%↑

JNJ

209.35

+0.9%↑

ABBV

231.6

+0.63%↑

UNH

330.51

-0.33%↓

AZN

92.71

-0.19%↓

LLY

1,078.02

+0.1%↑

JNJ

209.35

+0.9%↑

ABBV

231.6

+0.63%↑

UNH

330.51

-0.33%↓

AZN

92.71

-0.19%↓

LLY

1,078.02

+0.1%↑

JNJ

209.35

+0.9%↑

ABBV

231.6

+0.63%↑

UNH

330.51

-0.33%↓

AZN

92.71

-0.19%↓

LLY

1,078.02

+0.1%↑

JNJ

209.35

+0.9%↑

ABBV

231.6

+0.63%↑

UNH

330.51

-0.33%↓

AZN

92.71

-0.19%↓

LLY

1,078.02

+0.1%↑

JNJ

209.35

+0.9%↑

ABBV

231.6

+0.63%↑

UNH

330.51

-0.33%↓

AZN

92.71

-0.19%↓

Home・Akciju saraksts・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Atvērts

16.6 -0.24

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

16.46

Max

16.73

Galvenie mērījumi
By Trading Economics
Ienākumi	35M 9.5M
Pārdošana	35M 94M
EPS	0.06
Peļņas marža	10.158
Darbinieki	619
EBITDA	35M 17M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+23.35% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	17M 2.7B
Iepriekšējā atvēršanas cena	16.84
Iepriekšējā slēgšanas cena	16.6

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bullish Evidence

8.81 / 10.18 Atbalsts un pretestība

Adaptive Biotechnologies Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 24. dec. 21:41 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

2025. g. 28. dec. 23:57 UTC

Peļņas

'Avatar: Fire and Ash' Tops Domestic Box Office Again -- Barrons.com

2025. g. 28. dec. 23:48 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 28. dec. 23:48 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 28. dec. 23:48 UTC

Tirgus saruna

Nikkei May Rise on Weaker Yen -- Market Talk

2025. g. 28. dec. 10:30 UTC

Iegādes, apvienošanās, pārņemšana

There's No Happy Ending for Movie Theaters, No Matter Who Wins Warner -- Heard on the Street -- WSJ

2025. g. 26. dec. 20:22 UTC

Tirgus saruna

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

2025. g. 26. dec. 20:13 UTC

Tirgus saruna

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

2025. g. 26. dec. 19:24 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

2025. g. 26. dec. 17:45 UTC

Tirgus saruna

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

2025. g. 26. dec. 15:52 UTC

Tirgus saruna

Oil Futures Turn Lower After Steady Start -- Market Talk

2025. g. 26. dec. 14:58 UTC

Tirgus saruna

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

2025. g. 26. dec. 14:41 UTC

Tirgus saruna

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

2025. g. 26. dec. 14:28 UTC

Tirgus saruna

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

2025. g. 26. dec. 13:47 UTC

Tirgus saruna

Oil Futures Steady in Thin Holiday Trade -- Market Talk

2025. g. 26. dec. 07:22 UTC

Tirgus saruna

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

2025. g. 26. dec. 05:03 UTC

Tirgus saruna

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

2025. g. 26. dec. 03:38 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 26. dec. 03:38 UTC

Tirgus saruna

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

2025. g. 26. dec. 02:44 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 26. dec. 02:44 UTC

Tirgus saruna

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

2025. g. 26. dec. 01:39 UTC

Tirgus saruna

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

2025. g. 26. dec. 01:14 UTC

Tirgus saruna

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

2025. g. 26. dec. 00:34 UTC

Tirgus saruna

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

2025. g. 26. dec. 00:15 UTC

Tirgus saruna

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

2025. g. 25. dec. 23:42 UTC

Tirgus saruna

Nikkei May Trade in Range; Yen in Focus -- Market Talk

2025. g. 25. dec. 23:40 UTC

Tirgus saruna

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

2025. g. 25. dec. 00:20 UTC

Iegādes, apvienošanās, pārņemšana

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

2025. g. 24. dec. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

2025. g. 24. dec. 21:26 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

Salīdzinājums

Cenas izmaiņa

Adaptive Biotechnologies Corp Prognoze

Cenas mērķis

By TipRanks

23.35% augšup

Prognoze 12 mēnešiem

Vidējais 20.6 USD 23.35%

Augstākais 22 USD

Zemākais 20 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Adaptive Biotechnologies Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

7 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 7 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Adaptive Biotechnologies Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

8.81 / 10.18Atbalsts un pretestība

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.